Mithra Receives acceptance of Marketing Authorization Application (MAA) to market Estelle® in Belgium and Luxembourg

Liege, Belgium, 03 March 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the European Medicines Agency (EMA) has accepted its regulatory submission to market Estelle® in Belgium and Luxembourg.  Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).